Zholkiver K I, Kim O M
Vopr Onkol. 1979;25(3):60-3.
Application of moving telegamma therapy as an adjunct to the associated radiation treatment in 399 patients allowed an increase of the dosage up to 6500 rad in the parametrium area. A 5-year survival in stage I was 91.6 +/- 10.5%, in stage II--63.3 +/- 4.7% and in stage III--48 +/- 5.6%. Late postirradiation rectitis was noted in 24 patients, cystitis--in 8 and rectal fistula--in 7.
对399例患者应用移动远距γ疗法作为相关放射治疗的辅助手段,使子宫旁组织区域的剂量增加至6500拉德。I期患者的5年生存率为91.6±10.5%,II期为63.3±4.7%,III期为48±5.6%。24例患者出现晚期放射性直肠炎,8例出现膀胱炎,7例出现直肠瘘。